Teva and Lonza announce to discontinue Biologics Joint Venture

29-Jul-2013 - Teva Pharmaceutical Industries and Lonza Group announced that following a strategic review of the Teva-Lonza Joint Venture (TL-JV), the companies have decided to discontinue their collaboration for the development, manufacturing and marketing of biosimilars. The discontinuation of the TL-JV, ...

Researchers from BGU have generated a promising drug candidate for the treatment of Psoriasis

27-Feb-2013 - Researchers from the Department of Life Sciences and the National Institute for Biotechnology in the Negev at Ben-Gurion University of the Negev in collaboration with Teva pharmaceutical industries LTD. have engineered a natural immune system receptor into a promising drug candidate for the ...

Teva Announces FDA Grants Approval for Tbo-filgrastim for the Treatment of Chemotherapy-Induced Neutropenia

03-Sep-2012 - Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted approval for tbo-filgrastim (XM02 filgrastim), the first new granulocyte colony-stimulating factor (G-CSF) to be approved in the United States in more than 10 years. Tbo-filgrastim is a ...

Synthon sued for infringing certain patents for Copaxone

Synthon intends to defend vigorously

10-Apr-2012 - Synthon has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for glatiramer acetate, 20 mg/ml solution for injection in pre-filled syringes. The reference listed drug for glatiramer acetate is Copaxone, indicated for reduction of the frequency of ...

Investigational Laquinimod demonstrates its potential as a new oral treatment for RRMS

21-Oct-2011 - Teva Pharmaceutical Industries Ltd. and Active Biotech announced the presentation of Phase III clinical and pre-clinical data, which collectively demonstrate that once-daily oral laquinimod modulates the pathological processes of multiple sclerosis to impact disease activity, disability ...

Results of Phase III Bravo trial reinforce unique profile of laquinimod for multiple sclerosis treatment

Primary endpoint of reducing annualized relapse rate was not statistically achieved

02-Aug-2011 - Teva Pharmaceutical Industries Ltd. and Active Biotech announced initial results from the Phase III BRAVO study, which was designed to evaluate the efficacy, safety and tolerability of oral laquinimod compared to placebo and to provide a benefit-risk assessment comparing oral laquinimod and a ...

Teva announces successful results of Phase III with oral laquinimod for multiple sclerosis

10-Dec-2010 - Teva Pharmaceutical Industries Ltd. and Active Biotech announced initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in ...

Merck KGaA Sells Théramex To Teva for EUR 265 million

Acquisition will provide Teva with a strong platform to expand its Global Women’s Health Business

01-Nov-2010 - Merck KGaA announced that it will sell Théramex, its Monaco-based pharmaceutical company specialized in women’s health and gynecology, to Teva. Merck and Teva have signed an agreement whereby Teva will acquire all Théramex operations including 100% of the shares of Théramex S.A.M of Monaco and ...

Teva and Oncogenex annouce initiation of second Phase 3 trial of Custirsen

04-Oct-2010 - Teva Pharmaceuticals Industries Ltd.and OncoGenex Pharmaceuticals, Inc. announced the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC). The SYNERGY trial is the ...

TEMPO study further demonstrates the benefits of Azilect in early Parkinson's disease patients

Newly published data confirms long term efficacy, safety and tolerability in treating early Parkinson's disease

09-Aug-2010 - H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd. announced newly published long-term data on Azilect® (rasagiline tablets) from the TEMPO study and its open-label extension. The findings confirm the long-term efficacy, safety and tolerability of Azilect® in patients with Parkinson's ...